Successful Treatment of Refractory Polymyositis with Pulse Intravenous Cyclophosphamide and Low-dose Weekly Oral Methotrexate Therapy.
スポンサーリンク
概要
- 論文の詳細を見る
A 36-year-old woman gradually developed dysphagia and muscle weakness of the lower extremities. Diagnosis of polymyositis was given from elevation of serum creatine kinase and pathological findings of a muscle biopsy. Despite oral prediiisolone and intravenous pulse methylprednisolone therapy, her muscle weakness persisted, and then pulse intravenous cyclophosphamide (IVCY) therapy was initiated and repeated five times in total, which resulted in significant improvement in muscle strength. Thereafter, weekly administration of methotrexate at low dosage further normalized the serum creatine kinase level. We may conclude that IVCY and low-dose weekly methotrexate together could be an alternative in refractory polymyositis.(Internal Medicine 32: 749-752 1993)
- 社団法人 日本内科学会の論文
著者
-
Miura Takanori
The Second Department Of Internal Medicine Asahikawa Medical College
-
FUKAWA Etsushi
the Second Department of Internal Medicine, Asahikawa Medical College
-
HIRANO Fuminori
the Second Department of Internal Medicine, Asahikawa Medical College
-
MAKINO Isao
the Second Department of Internal Medicine, Asahikawa Medical College
-
Makino Yuichi
The Second Department Of Internal Medicine Asahikawa Medical College
-
Tanaka Hirotoshi
The Second Department Of Internal Medicine Asahikawa Medical College
-
NOMURA Yoshinobu
the Second Department of Internal Medicine, Asahikawa Medical College
-
MATSUI Tomoko
the Second Department of Internal Medicine, Asahikawa Medical College
関連論文
- Nuclear factor-kB regulates RANTES chemokine expression in response to tumor necrosis factor-α in fibroblast-like synoviocytes
- Human T Cell Leukemia Virus Type I-associated Myelopathy in a Patient with Systemic Lupus Erythematosus
- Effect of ursodeoxycholic acid and chenodeoxycholic acid on major histocompatibility complex class I gene expression.
- Successful Treatment of Refractory Polymyositis with Pulse Intravenous Cyclophosphamide and Low-dose Weekly Oral Methotrexate Therapy.